These data indicate that the anti-GIPR antibody 2.63.1, as a potential therapeutic approach for obesity, has demonstrated certain weight-reducing effects in animal models
DSIP has not provided one
To find out more about it, keep reading
MENLO PARK, Calif., May 7, 2025 /PRNewswire/ -- Phenomix Sciences (Phenomix), the first commercial precision obesity medicine biotechnology company, in partnership with Mayo Clinic researchers, presented new findings at Digestive Disease Week (DDW) 2025 showing its proprietary machine-learning algorithms can predict which patients are more likely to experience side effects, specifically nausea, from GLP-1 therapies
Prebiotic potential and anti-inflammatory activity of soluble polysaccharides obtained from soybean residue
Umbrella Labs will continue to apply these controls where appropriate, with the objective of improving documentation clarity and record continuity for research procurement and multi-run bench workflows